Relationship of Cognition to Clinical Response in First-Episode Schizophrenia Spectrum Disorders

Schizophrenia Bulletin

Volumn 41, Issue 6, 2015, Pages 1237-1247

  Trampush, Joey W ^a,b,c   Lencz, Todd ^a,b,c   Derosse, Pamela ^a,b   John, Majnu ^a,b,c,d   Gallego, Juan A ^a,b,c   Petrides, Georgios ^a,b,c   Hassoun, Youssef ^a   Zhang, Jian Ping ^a,b,c   Addington, Jean ^e   Kellner, Charles H ^f   Tohen, Mauricio ^g   Burdick, Katherine E ^f   Goldberg, Terry E ^a,b,c   Kane, John M ^a,b,c   Robinson, Delbert G ^a,b,c   Malhotra, Anil K ^a,b,c  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^c DONALD AND BARBARA ZUCKER SCHOOL OF MEDICINE AT HOFSTRA NORTHWELL   (United States)

^d HOFSTRA UNIVERSITY   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Aripiprazole; Cognition; General cognitive function; Planning; Psychosis; Risperidone

Indexed keywords

ARIPIPRAZOLE; RISPERIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HUMAN; LEARNING; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MAZE TEST; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; POSITIVE SYNDROME; PRIORITY JOURNAL; PSYCHOSIS; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TASK PERFORMANCE; TREATMENT DURATION; TREATMENT RESPONSE; WORKING MEMORY; ADOLESCENT; COGNITION DISORDERS; COMPLICATION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PROCEDURES; PSYCHOTIC DISORDERS; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; COGNITION DISORDERS; FEMALE; HUMANS; MALE; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOTIC DISORDERS; REMISSION INDUCTION; RISPERIDONE; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84946144370     PISSN: 05867614     EISSN: 17451701     Source Type: Journal    
DOI: 10.1093/schbul/sbv120     Document Type: Article

References (54)

1. Gold JM, Dickinson D. "Generalized cognitive deficit" in schizophrenia: overused or underappreciated? Schizophr Bull. 2013;39:263-265.
2. Keefe RSE, Harvey PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol. 2012;213:11-37.
3. Kahn RS, Keefe RS. Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry. 2013;70:1107-1112.
4. Bilder RM, Reiter G, Bates J, et al. Cognitive development in schizophrenia: follow-back from the first episode. J Clin Exp Neuropsychol. 2006;28:270-282.
5. MacCabe JH, Wicks S, Löfving S, et al. Decline in cognitive performance between ages 13 and 18 years and the risk for psychosis in adulthood: a Swedish longitudinal cohort study in males. JAMA Psychiatry. 2013;70:261-270.
6. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549-559.
7. Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009;23:315-336.
8. Fatouros-Bergman H, Cervenka S, Flyckt L, Edman G, Farde L. Meta-analysis of cognitive performance in drug-naïve patients with schizophrenia. Schizophr Res. 2014;158:156-162.
9. Robinson DG, Woerner MG, Napolitano B, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. Am J Psychiatry. 2006;163:2096-2102.
10. Robinson DG, Gallego JA, John M, et al. A randomized comparison of aripiprazole and risperidone for the acute treatment of first-episode schizophrenia and related disorders: 3-month outcomes. Schizophr Bull. 2015:sbv125. doi:10.1093/schbul/sbv125.
11. Leucht S, Komossa K, Rummel-Kluge C, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry. 2009;166:152-163.
12. Gallego JA, Robinson DG, Sevy SM, et al. Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months? J Clin Psychiatry. 2011;72:1691-1696.
13. Kennedy JL, Altar CA, Taylor DL, Degtiar I, Hornberger JC. The social and economic burden of treatment-resistant schizophrenia: a systematic literature review. Int Clin Psychopharmacol. 2014;29:63-76.
14. Malhotra AK. Dissecting the heterogeneity of treatment response in first-episode schizophrenia. Schizophr Bull. 2015:sbv117. doi:10.1093/schbul/sbv117.
15. Keefe RS, Sweeney JA, Gu H, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry. 2007;164:1061-1071.
16. Harvey PD, Rabinowitz J, Eerdekens M, Davidson M. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial. Am J Psychiatry. 2005;162:1888-1895.
17. Keefe RS, Seidman LJ, Christensen BK, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry. 2004;161:985-995.
18. Goldberg TE, Goldman RS, Burdick KE, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect? Arch Gen Psychiatry. 2007;64:1115-1122.
19. Nuechterlein KH, Green MF, Kern RS, et al. The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry. 2008;165:203-213.
20. Keefe RS, Bilder RM, Davis SM, et al.; CATIE Investigators; Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry. 2007;64:633-647.
21. Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009;166:675-682.
22. Rund BR, Melle I, Friis S, et al. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis. Am J Psychiatry. 2004;161:466-472.
23. Heydebrand G, Weiser M, Rabinowitz J, Hoff AL, DeLisi LE, Csernansky JG. Correlates of cognitive deficits in first episode schizophrenia. Schizophr Res. 2004;68:1-9.
24. Chang WC, Hui CL, Chan SK, Lee EH, Wong GH, Chen EY. Relationship between diminished expression and cognitive impairment in first-episode schizophrenia: a prospective three-year follow-up study. Schizophr Res. 2014;152:146-151.
25. Wang J, Hu M, Guo X, Wu R, Li L, Zhao J. Cognitive effects of atypical antipsychotic drugs in first-episode drug-naïve schizophrenic patients. Neural Regen Res. 2013;8;277-286.
26. Riedel M, Schennach-Wolff R, Musil R, et al. Neurocognition and its influencing factors in the treatment of schizophrenia-Effects of aripiprazole, olanzapine, quetiapine and risperidone. Hum Psychopharmacol. 2010;25:116-125.
27. Hori H, Yoshimura R, Katsuki A, et al. The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients. J Psychiatr Res. 2012;46:757-761.
28. Yasui-Furukori N, Kaneda A, Sugawara N, Tomita T, Kaneko S. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients. J Psychopharmacol (Oxford). 2012;26:806-812.
29. Kirkpatrick B, Fenton WS, Carpenter WT, Marder SR. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32:214-219.
30. Nuechterlein KH, Barch DM, Gold JM, Goldberg TE, Green MF, Heaton RK. Identification of separable cognitive factors in schizophrenia. Schizophr Res. 2004;72:29-39.
31. First MB, Spitzer R, Gibbon M, Williams J. Structured Clinical Interview for Axis 1 DSM-IV Disorders Patient Edition. New York, NY: New York Biometrics Research Department, New York State Psychiatric Institute: 1998.
32. Funke B, Finn CT, Plocik AM, et al. Association of the DTNBP1 locus with schizophrenia in a U.S. population. Am J Hum Genet. 2004;75:891-898.
33. Woerner MG, Mannuzza S, Kane JM. Anchoring the BPRS: an aid to improved reliability. Psychopharmacol Bull. 1988;24:112-117.
34. Robinson D, Woerner M, Schooler N. Intervention research in psychosis: issues related to clinical assessment. Schizophr Bull. 2000;26:551-556.
35. Guy W. The clinical global impression scale. In: ECDEU Assessment Manual for Psychopharmacology, revised. Rockville, MD: US Dept. of Health, Education and Welfare, ADAMHA, NIMH Psychopharmacology Research Branch: 1976;218-222.
36. Nuechterlein KH, Green MF. MATRICS Consensus Cognitive Battery. Los Angeles, CA: MATRICS Assessment, Inc.; 2006.
37. Trampush JW, Lencz T, Knowles E, et al. Independent evidence for an association between general cognitive ability and a genetic locus for educational attainment. Am J Med Genet Part B Neuropsychiatr Genet. 2015;168:363-373.
38. SAS/STAT User's Guide, Version 9.1. Cary, NC: SAS Institute Inc. Vol. 3 1999.
39. Fritz MS, Mackinnon DP. Required sample size to detect the mediated effect. Psychol Sci. 2007;18:233-239.
40. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 1986;51:1173-1182.
41. Dickinson D, Ragland JD, Gold JM, Gur RC. General and specific cognitive deficits in schizophrenia: Goliath defeats David? Biol Psychiatry. 2008;64:823-827.
42. Reilly JL, Sweeney JA. Generalized and specific neurocognitive deficits in psychotic disorders: utility for evaluating pharmacological treatment effects and as intermediate phenotypes for gene discovery. Schizophr Bull. 2014;40:516-522.
43. Robinson DG, Woerner MG, Alvir JM, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry. 1999;156:544-549.
44. Torgalsbøen AK, Mohn C, Rishovd Rund B. Neurocognitive predictors of remission of symptoms and social and role functioning in the early course of first-episode schizophrenia. Psychiatry Res. 2014;216:1-5.
45. Zhou FC, Xiang YT, Wang CY, et al. Predictive value of prospective memory for remission in first-episode schizophrenia. Perspect Psychiatr Care. 2013;50:102-110.
46. Kirsch P, Lis S, Esslinger C, et al. Brain activation during mental maze solving. Neuropsychobiology. 2006;54:51-58.
47. Vakil E, Blachstein H, Soroker N. Differential effect of right and left basal ganglionic infarctions on procedural learning. Cogn Behav Neurol. 2004;17:62-73.
48. Sarpal DK, Argyelan M, Robinson DG, et al. Baseline striatal functional connectivity as a predictor of response to antipsychotic drug treatment. Am J Psychiatry.
49. Buchanan RW, Davis M, Goff D, et al. A summary of the FDA-NIMH-MATRICS workshop on clinical trial design for neurocognitive drugs for schizophrenia. Schizophr Bull. 2005;31:5-19.
50. Keefe RSE. The longitudinal course of cognitive impairment in schizophrenia: An examination of data from premorbid through posttreatment phases of illness. J Clin Psychiatry. 2014;75(suppl 2):8-13. doi:10.4088/JCP.13065su1.02.
51. Olivier MR, Killian S, Chiliza B, et al. Cognitive performance during the first year of treatment in first-episode schizophrenia: a case-control study. Psychol Med. 2015;22:1-11.
52. Benoit A, Bodnar M, Malla AK, Joober R, Bherer L, Lepage M. Changes in memory performance over a 12-month period in relation to achieving symptomatic remission after a firstepisode psychosis. Schizophr Res. 2014;153:103-108.
53. Ventura J, Thames AD, Wood RC, Guzik LH, Hellemann GS. Disorganization and reality distortion in schizophrenia: a meta-analysis of the relationship between positive symptoms and neurocognitive deficits. Schizophr Res. 2010;121:1-14.
54. Wykes T, Spaulding WD. Thinking about the future cognitive remediation therapy-what works and could we do better? Schizophr Bull. 2011;37(suppl 2):S80-S90.